ATE517926T1 - Antikörper zur hemmung der aktivität von mmp-2 und mmp-9 - Google Patents

Antikörper zur hemmung der aktivität von mmp-2 und mmp-9

Info

Publication number
ATE517926T1
ATE517926T1 AT04725641T AT04725641T ATE517926T1 AT E517926 T1 ATE517926 T1 AT E517926T1 AT 04725641 T AT04725641 T AT 04725641T AT 04725641 T AT04725641 T AT 04725641T AT E517926 T1 ATE517926 T1 AT E517926T1
Authority
AT
Austria
Prior art keywords
mmp
activity
antibodies
inhibit
antibody
Prior art date
Application number
AT04725641T
Other languages
English (en)
Inventor
Irit Sagi
Tamar Danon
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE517926T1 publication Critical patent/ATE517926T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04725641T 2003-04-04 2004-04-04 Antikörper zur hemmung der aktivität von mmp-2 und mmp-9 ATE517926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46000503P 2003-04-04 2003-04-04
PCT/IL2004/000308 WO2004087042A2 (en) 2003-04-04 2004-04-04 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins

Publications (1)

Publication Number Publication Date
ATE517926T1 true ATE517926T1 (de) 2011-08-15

Family

ID=33131910

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04725641T ATE517926T1 (de) 2003-04-04 2004-04-04 Antikörper zur hemmung der aktivität von mmp-2 und mmp-9

Country Status (6)

Country Link
US (4) US7524938B2 (de)
EP (2) EP2330132B1 (de)
AT (1) ATE517926T1 (de)
DK (2) DK1610678T3 (de)
ES (2) ES2369498T3 (de)
WO (1) WO2004087042A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE517926T1 (de) 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
WO2006086730A2 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
US7745587B2 (en) 2005-12-30 2010-06-29 Dyax Corp. Antibodies that bind MMP-14
EP2155691B1 (de) * 2007-02-23 2016-01-13 Yeda Research and Development Co. Ltd. Antikörper und sie enthaltende pharmazeutische zusammensetzungen verwendbar zur hemmung der aktivität von metalloproteinen
US8536313B2 (en) 2007-07-10 2013-09-17 Shionogi & Co., Ltd. Monoclonal antibody having neutralizing activity against MMP13
BRPI0814479A2 (pt) 2007-08-15 2016-07-12 Yeda Res & Dev "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
WO2009079581A1 (en) * 2007-12-17 2009-06-25 Dyax Corp. Evaluating mmp expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
US8013125B2 (en) * 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517662A (ja) 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
EP2323736A1 (de) * 2008-09-09 2011-05-25 University of East Anglia Behandlung von fibrotischen augenerkrankungen mit einem mmp2-inhibitor
CN101559076B (zh) * 2009-05-27 2012-08-29 西北大学 抗肿瘤基质金属蛋白酶抑制剂
CN102822202B (zh) 2010-01-27 2015-07-22 耶达研究及发展有限公司 抑制金属蛋白的抗体
WO2012027721A2 (en) 2010-08-27 2012-03-01 Gilead Biologics, Inc Antibodies to matrix metalloproteinase 9
CN103370337B (zh) 2010-10-28 2015-12-09 耶达研究及发展有限公司 用于产生针对金属酶的抗体的方法
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
JP2015506369A (ja) * 2012-01-30 2015-03-02 アレコー リミテッド 安定化された水性抗体組成物
MD20140108A2 (ro) * 2012-02-29 2015-03-31 Gilead Biologics, Inc. Anticorpi împotriva metaloproteinazei 9 matriciale
KR102657653B1 (ko) 2017-07-18 2024-04-16 다이이찌 산쿄 가부시키가이샤 활성형 mmp-9 결합 펩티드
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
KR20250095278A (ko) * 2023-12-19 2025-06-26 주식회사 메디아크 포르피린-기반의 금속-유기 골격체를 포함하는 대식세포 분극화 유도용 조성물 및 이의 용도

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4743587A (en) 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5525629A (en) 1992-04-07 1996-06-11 British Bio-Technology Limited Inhibition of cytokine production
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5679548A (en) 1993-02-02 1997-10-21 The Scripps Research Institute Methods for producing polypeptide metal binding sites and compositions thereof
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US5800814A (en) 1994-04-22 1998-09-01 Oklahoma Medical Research Foundation Method for inhibition of breast tumor growth
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
WO1995029689A1 (en) 1994-04-28 1995-11-09 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
US5629980A (en) * 1994-11-23 1997-05-13 Xerox Corporation System for controlling the distribution and use of digital works
ES2185750T3 (es) 1995-08-08 2003-05-01 Ono Pharmaceutical Co Derivados de acido hidroxamico utiles para la inhibicion gelatinasa.
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
WO1997024117A1 (en) 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
EP0994104A4 (de) 1996-06-27 2001-09-12 Ono Pharmaceutical Co Aryl-sulfid-, -sulfoxid- und -sulfon-derivate und arzneimittel die diese als aktiven inhaltsstoff enthalten
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP3673888B2 (ja) 1998-03-09 2005-07-20 独立行政法人科学技術振興機構 ポルフィリン類金属錯体の製造方法
OA11589A (en) 1998-07-30 2004-07-30 Warner Lambert Co Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases.
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
AU2002352089A1 (en) * 2001-11-23 2003-06-10 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
ATE517926T1 (de) 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9

Also Published As

Publication number Publication date
US20090208510A1 (en) 2009-08-20
US7524938B2 (en) 2009-04-28
EP1610678B1 (de) 2011-07-27
EP2330132B1 (de) 2013-08-14
EP2330132A1 (de) 2011-06-08
US20070172482A1 (en) 2007-07-26
US20140370031A1 (en) 2014-12-18
WO2004087042A3 (en) 2005-07-14
US8841108B2 (en) 2014-09-23
ES2433440T3 (es) 2013-12-11
EP1610678A4 (de) 2008-04-09
US20120003236A1 (en) 2012-01-05
WO2004087042A2 (en) 2004-10-14
DK1610678T3 (da) 2011-10-24
DK2330132T3 (da) 2013-11-04
ES2369498T3 (es) 2011-12-01
EP1610678A2 (de) 2006-01-04

Similar Documents

Publication Publication Date Title
DK1610678T3 (da) Antistoffer til inhibering af aktiviteten af MMP-2 og MMP-9
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
DK1257584T3 (da) Humaniserede antistoffer, som sekvestrerer
TW200514790A (en) Bispecific antibody substituting for functional protein
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
ATE504315T1 (de) Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen
DE60236646D1 (de) Anti-VEGF-2 Antikörper
SI1624891T2 (sl) Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
ATE437184T1 (de) Varianten der fc-region
CO6220978A2 (es) Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos
DE60236965D1 (de) Coronavirus-ähnliche partikel enthaltende funktionell deletierte genome
ATE415423T1 (de) Immunisierungstherapie zur behandlung von atherosklerose
DE60128914D1 (de) Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation
WO2003048207A3 (en) Anti-dota antibody
DK1636561T3 (da) Kombinatorisk proteinbiblioteksscreening ved hjælp af periplasmatisk ekspression
DE60331598D1 (de) Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
ATE364396T1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE69839767D1 (de) Verwendung von 15-keto-prostaglandin-e verbindungen als endothelin antagonisten
GB0324656D0 (en) A protein involved in ovarian cancer
EP1789027A4 (de) Therapeutische verwendung von anti-tf-antigen-antikörper
DE602004023199D1 (de) Fluoreszenzprotein und pigmentprotein
ATE541047T1 (de) Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties